CABG Medical Announces Commencement of Clinical Trials in Europe
12 9월 2005 - 10:50PM
PR Newswire (US)
MINNEAPOLIS, Sept. 12 /PRNewswire-FirstCall/ -- CABG Medical, Inc.
(NASDAQ:CABG) today announced the commencement of enrollment in its
European clinical trial of the Holly Graft(TM) System, a drug
eluting graft (DEG) for facilitating a coronary artery bypass
procedure. The Company announced that a total of three patients
were treated with the Holly Graft System in Hannover, Germany.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO )
"The initiation of our clinical trials in European markets, such as
Germany, represents a significant milestone for the Company," said
Manny Villafana, Chairman and CEO. "Additionally, we are very
pleased to be collaborating with respected surgeons and cardiac
programs throughout the European Union." The patients were treated
by Prof. Dr. Uwe Klima, M.D., a cardiac surgeon at the Medizinische
Hochschule Hannover in Hannover, Germany. "This represents the
first step in a true advancement for cardiac surgery and to advance
our goal of less invasive procedures for coronary bypass.
Additionally, the introduction of drug-eluting technology,
represents a new opportunity to improve patients outcomes,"
Professor Klima commented. "Time and results will determine the
place of the Holly Graft System as a source of conduit." In keeping
with its historical policy on disclosure, CABG does not intend to
provide press releases documenting individual human cases going
forward. In this case, however, the initiation of human cases in
Europe, constitutes a significant development for the Company,
thereby warranting a news release to the investment community.
About CABG Medical CABG Medical, Inc. is a medical technology
company developing technologies and therapies to improve the
treatment of coronary heart disease by advancing conventional
bypass surgery. We have designed our first product, the Holly
Graft(TM) System, by leveraging our understanding of flow dynamics,
material sciences and drug combinations to create a drug-eluting
graft (DEG) system. Safe Harbor This Press Release contains
forward-looking statements that may include statements regarding
intent, belief or current expectations of the Company and its
management. Actual results could differ materially from those
projected in the forward-looking statements as a result of a number
of important factors, including regulatory actions, competition,
and management of growth. For a discussion of these and other risks
and uncertainties that could affect the Company's activities and
results, please refer to the Company's filings with the Securities
and Exchange Commission.
http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO
http://photoarchive.ap.org/ DATASOURCE: CABG Medical, Inc. CONTACT:
Manny Villafana, Chairman & CEO, or John L. Babitt, President
& CFO, both of CABG Medical, Inc., +1-763-258-8005, Fax
+1-763-258-8008
Copyright
Cabg Medical (NASDAQ:CABG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Cabg Medical (NASDAQ:CABG)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Cabg Medical (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Cabg Medical (MM) News Articles